Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: testify (1), bear witness (18)

DVdSC (weekly cycles 9 onwards) DaratumumabSC-Bortezomib-Dexamethasone Ver1

Description: Chemotherapy Protocol Myeloma DVd SC (weekly) Bortezomib Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Borte
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles-9-onwards-DaratumumabSC-Bortezomib-Dexamethasone-Ver1.pdf

Docetaxel

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) DOCETAXEL (75) Regimen NSCLC – Docetaxel (75
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Docetaxelver12.pdf

Gemcitabine

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) GEMCITABINE Regimen NSCLC - Gemcitabine Indication Second line therapy of stage I
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Gemcitabinever12.pdf

Vinorelbine (oral day 1, 8 and 15)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) VINORELBINE (Oral) (Day 1, 8, 15) This protocol may require funding Regimen NSCLC – Vinorelbin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Vinorelbineoralday18and15ver11.pdf

Vinorelbine (oral day 1 and 8)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) VINORELBINE (Oral) (Day 1 and 8) This protocol may require funding Regimen NSCLC –
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Vinorelbineoralday1and8ver11.pdf

Vinorelbine (intravenous)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) VINORELBINE (Intravenous) Regimen NSCLC - Vinorelbine (Intravenous) Indication Se
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Vinorelbineintravenousver12.pdf

Nivolumab ver 1 (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab This regimen may require funding. Regimen NSCLC – Nivolumab Indication Metas
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-ver-1.pdf

Pembrolizumab 400mg (bladder)

Description: Chemotherapy Protocol BLADDER CANCER Pembrolizumab (400mg) Regimen • Bladder – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated for loca
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (bladder)

Description: Chemotherapy Protocol BLADDER CANCER Pembrolizumab (200mg) Regimen • Bladder – Pembrolizumab (200mg) Indication • Pembrolizumab is indicated for loca
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-200mg.pdf

Nivolumab 480mg (renal)

Description: Chemotherapy Protocol RENAL CELL CANCER Nivolumab (480mg-28 days) Regimen • Renal Cell – Nivolumab (480mg-28 days) Indication • Nivolumab is reco
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Nivolumab-480mg.pdf

191 to 200 of 354

Previous … 18 19 20 21 22 … Next